Skip to main content

Table 1 Baseline characteristics according to PA

From: Implantable device measured objective daily physical activity as a predictor of long-term all-cause mortality and cardiac death in patients with age > 75 years and high risk of sudden cardiac death: a cohort study

 

Total

(N = 133)

PA ≤ 6.47%

(n = 60)

PA > 6.47%

(n = 73)

P-value

Demographics

 Age, years

79.52 ± 3.68

79.86 ± 3.76

79.23 ± 3.62

0.325

 Male, n(%)

99 (74.4)

46 (76.7)

53 (72.6)

0.691

 BMI, Kg/m2

23.17 ± 2.90

23.42 ± 2.93

23.00 ± 2.87

0.371

 NYHA III/IV, n(%)

83 (62.4)

42 (50.6)

41 (49.4)

0.109

 PA,%

7.85 ± 4.64

3.99 ± 1.77

11.03 ± 3.77

< 0.001

 CRT-D, n(%)

34 (25.6)

17 (28.3)

17 (23.3)

0.553

 Primary prevention, n(%)

66 (49.6)

29 (48.3)

37 (50.7)

0.862

Comorbidities

 ICM, n(%)

69 (51.9)

32 (53.3)

37 (50.7)

0.862

 HTN, n(%)

62 (46.6)

24 (40.0)

38 (52.1)

0.221

 DM, n(%)

21 (15.8)

14 (23.3)

7 (9.6)

0.034

 Stroke, n(%)

5 (3.8)

3 (5.0)

2 (2.7)

0.657

 AF, n(%)

17 (12.8)

8 (13.3)

9 (12.3)

1.000

 Syncope, n(%)

27 (20.3)

14 (23.3)

13 (17.8)

0.517

Echocardiography

 LVEF, %

42.00 ± 13.53

41.90 ± 14.25

42.09 ± 13.00

0.936

 LVEDD, mm

58.13 ± 11.62

56.47 ± 10.13

59.50 ± 12.61

0.134

Medication

 ACEI/ARB, n(%)

55 (41.4)

27 (45.0)

28 (38.4)

0.482

 β-blocker, n(%)

70 (52.6)

29 (48.3)

41 (56.2)

0.388

 Amiodarone, n(%)

39 (29.3)

18 (30.0)

21 (28.8)

1.000

 Diuretic, n(%)

53 (39.8)

28 (46.7)

25 (34.2)

0.159

  1. Values are expressed as the mean ± SD or n (%)
  2. Abbreviations: ACEI Angiotensin-converting enzyme inhibitor, AF Atrial fibrillation, ARB Angiotensin receptor blocker, BMI Body Mass Index, CRT-D Cardiac resynchronization therapy defibrillator, DM Diabetes mellitus, HTN Hypertension, ICD Implantable cardioverter-defibrillator, ICM Ischemic cardiomyopathy, LVEDD Left ventricular end-diastolic dimension, LVEF Left ventricular ejection fraction, NYHA class New York Heart Association class, PA Physical activity